Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 8/20 | 0.50 |
| ▸ | PPARA | Q07869 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.49 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 3/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13960330 | 0.92 | SLC6A2 (0.54) | LMNAABCC4GAATSHRPTGS1 | |
| SCHEMBL454095 | 0.91 | CES2 (0.52) | PTGS1KMT2AMEN1 | |
| SCHEMBL176064 | 0.86 | FNTA (0.59) | MME | |
| SCHEMBL16431461 | 0.86 | FNTA (0.59) | MME | |
| SCHEMBL3353929 | 0.82 | MME (0.60) | LMNAABCC4GAATSHRPTGS1 | |
| SCHEMBL8380411 | 0.78 | CYP1A2 (0.50) | PTGS1 | |
| SCHEMBL8919717 | 0.78 | CYP1A2 (0.50) | PTGS1 | |
| SCHEMBL450960 | 0.78 | SLC6A2 (0.56) | — | |
| SCHEMBL109575 | 0.78 | CYP1A2 (0.50) | PTGS1 | |
| SCHEMBL2625190 | 0.77 | LMNA (0.62) | LMNAABCC4GAATSHRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| WO-2009009041-A2 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | MAP3K6, MAP3K4, MAP3K3 | LMNA 2046/4885ABCC4 4576/4885GAA 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.